Immunomodulation for type 1 diabetes mellitus.
Type 1 diabetes (T1D) is characterised by immune-mediated pancreatic islet beta-cell destruction. The initial immune response engenders secondary and tertiary responses which collectively result in impairment of beta-cell function, progressive destruction of beta-cells and consequent development of T1D. The process is insidious and may evolve over many years, with the overt expression of clinical symptoms becoming apparent only when most beta-cells have been destroyed. Over the last quarter century much investigation has been directed at interdicting the T1D disease process, both during the stage of evolution of the disease and at the time of disease onset. This chapter of the Yearbook of Advanced Technology and Treatments in Diabetes reviews the key articles that have appeared in this field between January 2008 and June 2009.
Skyler
J S
JS
Division of Endocrinology, Diabetes, and Metabolism, and Diabetes Research Institute, University of Miami, Miller School of Medicine, Miami, FL 33101-6960, USA. skyler@miami.edu
D003922:Diabetes Mellitus, Type 1 / Q000276:immunology / Q000628:therapy*; D006801:Humans; D056747:Immunomodulation